Skyrocketing specialty drug cost hurts wallets

Jun 25, 2015

The rising cost of specialty drugs to treat complex, chronic or life-threatening conditions has the potential to break the pocket books of businesses, consumers, insurance companies and the state, according to Milam Ford of Blue Cross and Blue Shield of Louisiana. Read More

ICYMI – Where’s Robert Stack When You Need Him?

May 5, 2015

ICYMI May 5, 2015  The New York Times: Runaway Drug Prices How companies set Read More

ICYMI: High Drug Costs Impact Wall Street and Spark a New Initiative in the White House

Apr 28, 2015

April 28, 2015 Note: Distributing the New York Times article below is not an Read More

ICYMI: National Journal article features CSRxP’s White Paper

Apr 21, 2015

This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.” Read More

New Drug Report Confirms Drug Prices On Unsustainable Path

Mar 11, 2015

Reaction from National Coalition on Health Care President and CEO John Rother Read More

[WSJ] Will Gilead’s Hepatitis C Drug Bust State Budgets?

Jul 17, 2014

Will the cost of new hepatitis C treatments bust state budgets? A new analysis Read More

[The Health Care Blog] The Coming Debate Over Specialty Drugs

Jul 2, 2014

The debate over the price of specialty drugs is intensifying and could well be Read More